Welcome to LookChem.com Sign In|Join Free
  • or
N-(2-chloro-6-trifluoromethyl-phenyl)-phthalimide is a chemical compound with the molecular formula C15H7ClF3NO2. It is a derivative of phthalimide, featuring a 2-chloro-6-trifluoromethyl-phenyl group attached to the nitrogen atom. N-(2-chloro-6-trifluoromethyl-phenyl)-phthalimide is characterized by its aromatic structure, with the chlorine and trifluoromethyl groups providing it with unique electronic and steric properties. It is often used in the synthesis of various pharmaceuticals and agrochemicals due to its potential to act as a building block for more complex molecules. The presence of the halogen and fluorine atoms can influence the reactivity and selectivity of the compound in chemical reactions, making it a valuable intermediate in organic synthesis.

361-17-1

Post Buying Request

361-17-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

361-17-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 361-17-1 includes 6 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 3 digits, 3,6 and 1 respectively; the second part has 2 digits, 1 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 361-17:
(5*3)+(4*6)+(3*1)+(2*1)+(1*7)=51
51 % 10 = 1
So 361-17-1 is a valid CAS Registry Number.

361-17-1Relevant academic research and scientific papers

N-phenyl-N'-pyridinylureas as anticonvulsant agents

Pavia,Lobbestael,Taylor,Hershenson,Miskell

, p. 854 - 861 (2007/10/02)

A series of N-phenyl-N'-pyridinylureas was examined for anticonvulsant activity. Extensive structure/activity investigations revealed optimal activity in the N-(2,6-disubstituted-phenyl)-N'-(4-pyridinyl)urea series, with 37 exhibiting the best overall anticonvulsant profile. Compound 37 was effective against seizures induced by maximal electroshock but did not protect mice from clonic seizures produced by the convulsant pentylenetetrazol. The overall pharmacological profile suggests that 37 would be of therapeutic use in the treatment of generalized tonic-clonic and partial seizures. Compound 37 was selected for Phase 1 clinical trials.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 361-17-1